Skip to main content
Equibles
ADVB logo

ADVB · Advanced Biomed Inc.

Track ADVB — free

Use ADVB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADVB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.63 -0.17 (-4.47%)
Rebalance outlook locked
Going-concern doubt — cleared Oct 13, 2026

The latest filing no longer states the doubt (first flagged May 15, 2026).

View the 10-K filed Oct 13, 2026
Market Cap
$5.82M
Shares
1.65M
Volume · Oct 21 17.13K Avg daily vol (3M) 870.96K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.80 Open$4.25 Day$3.76–4.25 52W close$3.71–18.98 Avg vol 30d41K Short int19K · 1.1% float · 1.0d Short vol29% DataMar 2025–Oct 2026 Filing10-K · Oct 13

Up next

Latest filing: 10-K
filed Oct 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$6.68M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-4,883.8%
Trailing 12 months
P / E (TTM)
0.7
Trailing earnings · reciprocal yield 140.3%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$385,535
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+25.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.1%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −37%
below
Price vs 50-day avg −48%
below
RSI (14) 24
oversold
MACD trend Negative
52-week position 1%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −40%
trailing
6-month return −28%
trailing
YTD return −35%
this year
Relative strength −36%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow Distributing
-40% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.14% of float · ▲ +91.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
3 holders — mid 1-yr range
Squeeze score 35
low risk · 0–100
Fundamentals
Strong
EPS growth +268%
Y/Y
Free cash flow $-2.0M
Balance sheet $385.5K
net cash
Quant / Vol
risk profile
Very High
Volatility 169%
annualized · 1-yr
Max drawdown −80%
past year
ATR 18.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−37% Bearish
Price vs 50-day avg
−48% Bearish
RSI (14)
24 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow Distributing
-40% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.14% of float · ▲ +91.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
3 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $4 Now $4 · 1% Range high $19
vs 200-day avg -37% vs 50-day avg -48%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ADVB
Advanced Biomed Inc.
this stock
$5.82M — — — 1.1%
TMO
Thermo Fisher Scientific Inc.
 $258.56B +18.6% +14.5% 37.6 1.5%
DHR
Danaher Corp
 $157.64B -2.0% +8.5% 39.8 1.3%
NTRA
Natera, Inc.
 $58.51B +77.2% -2.8% — 4.4%
A
Agilent Technologies, Inc.
 $50.00B +27.1% +6.4% 34.9 1.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
3
% held
0.1%
Net QoQ
-10.9K sh
Top holder
XTX Topco Ltd
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
18.9K
Days to cover
1.0d
Change
+9.1K sh
View
Short Volume
Short vol %
29%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
818
Value
$5.2K
As of
Sep 23, 2026
View
Off-Exchange
Off-exchange %
23.3%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$127.6K
Net income (FY)
$6.7M
EPS diluted
$5.33
View
Filings
SEC Filings
Latest
10-K
Filed
Oct 13, 2026
This year
18

Advanced Biomed Inc. acquired Acellent in April 2026, divested its biotechnology operations, generated $127,637 revenue and reported $6,677,077 net income for the fiscal year ended June 30, 2026.

View

Performance

5D 20D 120D MTD YTD
ADVB -26.4% -40.4% -28.3% -39.0% -34.9%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -25.2% -39.9% -36.4% -39.8% -47.7%
Key facts CIK 1941029 CUSIP 00752P203 Visit website